Search | Clinical Trials Finder

Conditions: Pancreatic Neoplasms, Rectal Neoplasms
Interventions: Blue light, Amber light, Ambient White Light; Device · Other
Lead sponsor: Matthew Neal MD; Other
Eligibility: 19 Years to 80 Years
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: CLL / SLL, CLL (Chronic Lymphocytic Leukemia), SLL (Small Lymphocytic Lymphoma), Marginal Zone Lymphoma(MZL), Lymphoplasmacytic Lymphoma/Waldenström Macroglobulinemia
Interventions: Lonitoclax (ZE50-0134); Drug
Lead sponsor: Lomond Therapeutics Holdings, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 5
States / cities: Louisville, Kentucky • Chapel Hill, North Carolina • Cincinnati, Ohio + 2 more

Conditions: Prostate Cancer
Interventions: ES414; Biological
Lead sponsor: Aptevo Therapeutics; Industry
Eligibility: Male only
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 4
States / cities: San Francisco, California • Buffalo, New York • Temple, Texas + 1 more

Conditions: Radiation Retinopathy
Interventions: 0.5 mg ranibizumab, Targeted Retinal Photocoagulation (TRP); Drug · Procedure
Lead sponsor: Greater Houston Retina Research; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 4
States / cities: Dallas, Texas • Houston, Texas • Katy, Texas + 1 more

Conditions: High-Grade Glioma
Interventions: XRD-0394, Radiation Therapy, Surgical Resection; Drug · Radiation · Procedure
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years and older
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 1
States / cities: New York, New York

Conditions: Advanced/Metastatic Solid Tumors
Interventions: ADG126 Mono, ADG126-anti PD1, ADG126-ADG106; Biological
Lead sponsor: Adagene Inc; Industry
Eligibility: 18 Years and older
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 2
States / cities: Los Angeles, California • San Antonio, Texas

Conditions: Melanoma (Skin)
Interventions: NY-ESO-1 157-165 (165V), Nivolumab, gp100:280-288 (288V), Montanide ISA 51 vegetable grade (VG), Ipilimumab, Apheresis Procedure; Biological · Drug · Procedure
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 16 Years and older
Enrollment: 73 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2023
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Obesity
Interventions: Danuglipron, Atorvastatin, Rosuvastatin; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 82 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 3
States / cities: Anaheim, California • South Miami, Florida

Conditions: Breast Cancer, Breast Cancer Female, Metastatic Triple-Negative Breast Carcinoma, ER Positive Breast Cancer, HER2-negative Breast Cancer, HER2 Negative Breast Carcinoma, ER-negative Breast Cancer
Interventions: Datopotamab Deruxtecan; Drug
Lead sponsor: Nancy Lin, MD; Other
Eligibility: 18 Years and older
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 3
States / cities: Miami, Florida • Boston, Massachusetts • Durham, North Carolina

Conditions: Healthy Volunteers, Sjögren's Syndrome
Interventions: ASP5502, Placebo; Drug
Lead sponsor: Astellas Pharma Global Development, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 116 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Daytona Beach, Florida

Conditions: Advanced Solid Tumors
Interventions: Treatment with ARQ 197 in combination with gemcitabine; Drug
Lead sponsor: ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA); Industry
Eligibility: 18 Years and older
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 4
States / cities: Atlanta, Georgia • Oklahoma City, Oklahoma • Nashville, Tennessee + 1 more

Conditions: High-risk HPV Infection and Biopsy-proven CIN1
Interventions: R-enantiomer of 1,2-dioleoyl-3-trimethylammonium-propane chloride + Peptides from HPV-16 E6 and E7; Biological
Lead sponsor: PDS Biotechnology Corp.; Industry
Eligibility: 21 Years to 65 Years · Female only
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 2
States / cities: Port Jefferson, New York • The Bronx, New York

Conditions: Non-Muscle Invasive Bladder Cancer, NMIBC, High-risk Non-Muscle Invasive Bladder Cancer
Interventions: Not listed
Lead sponsor: Natera, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 1
States / cities: Austin, Texas

Conditions: HIV-1 Infection
Interventions: B/F/TAF (Adult Strength), B/F/TAF (Low Dose), B/F/TAF (TOS); Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 1 Month to 17 Years
Enrollment: 177 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2027
U.S. locations: 10
States / cities: Washington D.C., District of Columbia • Ft. Pierce, Florida • Gainesville, Florida + 7 more

Conditions: Ovary Cancer
Interventions: EC1456, 99mTc-Etarfolatide; Drug
Lead sponsor: Endocyte; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Concord, North Carolina

Conditions: Non-Small Cell Lung Cancer
Interventions: Divarasib, Pembrolizumab, Carboplatin, Cisplatin, Pemetrexed; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 320 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2032
U.S. locations: 16
States / cities: Duarte, California • Huntington Beach, California • Irvine, California + 12 more

Conditions: Drug Toxicity
Interventions: HPN-100, HPN-100 or Placebo, Placebo, Moxifloxacin; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 98 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Pompe Disease
Interventions: duvoglustat, rhGAA; Drug
Lead sponsor: Amicus Therapeutics; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 11
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Orange, California + 8 more

Conditions: Metabolic Disorders, Non-alcoholic Steatohepatitis
Interventions: AZD2693, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 73 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Glendale, California

Conditions: Alcohol Abuse
Interventions: Not listed
Lead sponsor: Boston Children's Hospital; Other
Eligibility: 12 Years to 21 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 4
States / cities: Belmont, Massachusetts • Boston, Massachusetts • Cambridge, Massachusetts

Conditions: Healthy
Interventions: ALXN1007, Placebo; Drug · Other
Lead sponsor: Alexion Pharmaceuticals, Inc.; Industry
Eligibility: 25 Years to 55 Years
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Small Cell Lung Cancer, Small Cell Lung Carcinoma
Interventions: 89Zr-DFO-SC16.56, SC16.56, Phase I, Cohort 2, SC16.56, Phase I, Cohort 3, SC16.56, Phase II; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Hematologic Malignancies
Interventions: SLS009, venetoclax, azacitidine; Drug
Lead sponsor: Sellas Life Sciences Group; Industry
Eligibility: 12 Years and older
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 19
States / cities: Birmingham, Alabama • Goodyear, Arizona • Phoenix, Arizona + 16 more

Conditions: Graves Disease
Interventions: MER511 (IV), Placebo comparator (IV), MER511 (SC), Placebo comparator (SC), MER511 (SC) for MAD, Placebo comparator (SC) for MAD; Biological
Lead sponsor: Merida Biosciences; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 11
States / cities: Torrance, California • Hollywood, Florida • Miami, Florida + 8 more

Search by objective public record fields.

Blue and Amber Light Exposure in Patients With Rectal and Pancreatic Cancer

A Study of Lonitoclax (ZE50-0134) in Relapsed or Refractory B-cell Malignancies

Study of ES414 in Metastatic Castration-Resistant Prostate Cancer

Study of the Efficacy and Tolerability of Intravitreal Injections of Ranibizumab Compared to Intravitreal Injections of Ranibizumab Combined With Targeted Retinal Photocoagulation to Treat Radiation Retinopathy.

Concurrent XRD-0394 With Radiation Therapy for High Grade Gliomas

ADG126, ADG126 in Combination With Anti PD1 Antibody, and ADG126 in Combination With ADG106 in Advanced/Metastatic Solid Tumors

Vaccine Combining Multiple Class I Peptides and Montanide ISA 51VG With Escalating Doses of Anti-PD-1 Antibody Nivolumab or Ipilimumab With Nivolumab For Patients With Resected Stages IIIC/ IV Melanoma

A Study to Learn How the Study Medicine Danuglipron is Taken Up Into the Blood and If Danuglipron Changes How the Body Processes Other Study Medicines (Atorvastatin and Rosuvastatin) in Healthy Adults Who Are Overweight or Obese

DATO-BASE: DATOpotamab-deruxtecan for Breast Cancer Brain metAstaSEs

A Study to Evaluate the Effects of ASP5502 in Healthy Adults and Adults With Primary Sjögren's Syndrome

Dose Escalation Study of ARQ 197 in Combination With Gemcitabine in Adult Patients With Advanced Solid Tumors

An Open-Label, Phase I, Escalating Dose Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of PDS0101

Sample Collection for Ongoing Research and Product Evaluation Study - Non-muscle Invasive Bladder Cancer (SCORE-NMIBC)

Study of Bictegravir/Emtricitabine/Tenofovir Alafenamide Fixed Dose Combination in Adolescents and Children With Human Immunodeficiency Virus-1

An Exploratory Study of the Folic Acid-tubulysin Conjugate EC1456 in Ovarian Cancer Subjects Undergoing Surgery

A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation

Double-Blind Randomized Crossover Trial to Access Electrocardiogram Effects of HPN-100

Drug-drug Interaction Study

A Study to Understand the Safety, Tolerability, and Activity of Drug in Body Over a Period of Time of AZD2693, in Subjects of Non-Childbearing Potential in Overweight But Otherwise Healthy Subjects, and Healthy Chinese and Japanese Subjects

Brain-imaging and Adolescent Neuroscience Consortium

Study to Evaluate Safety, Tolerability, PK and PD of ALXN1007 in Healthy Subjects

PET/CT Imaging of Small Cell Lung Cancer Using 89Zr-DFO-SC16.56

Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML

NEXUS Study: A Study to Test Single and Multiple Doses of MER511 Given to Adults With Graves' Disease